ICATA Asthma Mechanistic Study

Completed

Conditions studied: Asthma

In brief

The purposes of this study are to determine the effects of omalizumab on cells involved in the allergic response, to evaluate predictors of response to omalizumab, and to determine whether response to omalizumab therapy is influenced by the environment. A subset of inner-city children and adolescents currently enrolled in Inner-City Anti-IgE Therapy for Asthma (a clinical trial of omalizumab) will be enrolled in this study.

Key facts

Study ID

NCT00377390

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

224

Starts

2006-10-01

Expected to finish

2009-12-01

Last updated by the study team

2013-02-07

Who can join

Age: 6 and older, up to 20. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Currently enrolled in ICATA (ICAC-08, NCT00377572) Clinical Study
• Positive skin test to German cockroach required for participation in the basophil and T-cell studies and associated procedures
• Cockroach insensitive participants will serve as control groups

Where it is running

• Children's Memorial Hospital — Chicago, Illinois, United States
• Mount Sinai School of Medicine — New York, New York, United States
• Rainbow Babies and Children's Hospital — Cleveland, Ohio, United States
• University of Texas Southwestern Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.